FDA Approves First At-Home Brain Stimulation Device for Major Depression Treatment
核心洞察
The FDA has approved Flow Neuroscience (搜索)'s FL-100 (搜索) transcranial direct-current stimulation (搜索) system, marking the first at-home prescription neuromodulation therapy authorized in the US for adults with moderate to severe major depressive disorder (搜索).
The approval is based on a pivotal randomized controlled trial published in Nature Medicine showing active tDCS (搜索) produced significantly greater symptom reduction than sham treatment, with 58% of patients achieving remission by 10 weeks.
The device addresses a critical unmet need as more than 20 million US adults live with depression (搜索), representing a 60% increase over the past decade, with approximately one-third not responding adequately to antidepressant medications.
The FDA has granted approval to Flow Neuroscience (搜索)'s FL-100 (搜索) transcranial direct-current stimulation (搜索) (tDCS (搜索)) system, establishing it as the first at-home, prescription neuromodulation therapy authorized in the United States for adults with moderate to severe major depressive disorder (搜索) (MDD). The device will be available for prescription by clinicians as either a stand-alone or adjunctive treatment when it launches in the US market during the second quarter of 2026.
Addressing Growing Depression Crisis
The authorization comes at a critical time as depression (搜索) rates continue to escalate across the United States. More than 20 million US adults currently live with depression, representing a 60% increase over the past decade according to CDC data. The approval addresses a significant treatment gap, as approximately one-third of patients do not respond adequately to antidepressant medications or discontinue them due to adverse effects including sexual dysfunction, weight gain, and emotional blunting.
"We're on a mission to make effective, affordable non-drug treatment available to the millions of Americans suffering from depression (搜索)," said Erin Lee, CEO of Flow Neuroscience (搜索). "Flow's FDA approval is a watershed moment for the treatment of depression: the first step in moving from pharmaceutical treatments to tech-based therapies with minimal side effects."
Technology and Mechanism
The FL-100 (搜索) device delivers low-intensity electrical stimulation to the prefrontal cortex (搜索), the brain region responsible for mood regulation and stress response. This area often shows diminished activity in individuals with depression (搜索). The transcranial direct current stimulation technology underlying Flow has accumulated more than 25 years of clinical investigation across depression, post-stroke rehabilitation, pain conditions, and other neurologic indications, with over 9,000 publications supporting its use.
Flow reports that more than 55,000 people in Europe, the UK, Switzerland, and Hong Kong have already utilized the system, including within several NHS trusts. US access has expanded incrementally since the FDA awarded the device Breakthrough Device Designation in 2022.
Pivotal Clinical Evidence
The FDA's approval decision relies heavily on results from Flow's randomized, double-blind, sham-controlled trial published in Nature Medicine, which represents the largest remote tDCS (搜索) depression (搜索) study conducted to date. The 10-week trial enrolled 174 adults with at least moderately severe MDD, with baseline Hamilton Depression Rating Scale (HDRS) mean scores of 19 or higher. Participants self-administered either active or sham stimulation at home under remote supervision.
Active tDCS (搜索) demonstrated significantly greater symptom reduction compared to sham treatment, achieving a mean HDRS improvement of 9.41 points versus 7.14 points (95% CI, 0.51–4.01; P = 0.012). The treatment protocol consisted of 5 sessions per week for 3 weeks, followed by 3 sessions weekly for 7 weeks, and concluded with a 10-week open-label phase. Discontinuation rates remained similar between groups, and adverse events were generally mild and transient.
Clinical Outcomes and Real-World Performance
Active stimulation achieved 2- to 3-fold higher remission and response rates compared to sham treatment, with more than half (58%) of participants meeting remission criteria at 10 weeks. The study also reported positive results among participants receiving concurrent pharmacotherapy or psychotherapy, conditions more representative of real-world use than seen in most previous trials.
"Among our real world users, 77% see improvements in as little as three weeks. Such treatment, previously confined to clinics, can now be delivered at home, pointing to a scalable way of expanding access to effective depression (搜索) care," noted Kultar Garcha, MD, Flow's chief medical officer.
Safety Profile
Reported side effects are generally mild and transient, with the most common including skin dryness, irritation, or redness after prolonged use, transient headache, and stinging or itching at the stimulation site. Skin burns have occurred when electrode pads were reused or applied after drying out, highlighting the importance of proper device maintenance and usage protocols.
Market Access and Future Applications
The FL-100 (搜索) system requires a prescription from a licensed healthcare provider and is expected to be available for download through iOS and Android app stores in Q2 2026. The device is indicated for adults aged 18 years and older with moderate to severe major depressive disorder (搜索) in the current episode, either as monotherapy or as an adjunctive treatment, provided they are not considered treatment refractory.
"For more than 6 years since the device's launch in Europe, we've been building an evidence base globally with clinical trials, peer-reviewed research, and real-world case reports," said Daniel Månsson, Flow's co-founder and chief scientific officer. "The approval of FL-100 (搜索) in the US will now offer millions of patients an accessible and effective non-drug treatment option."
Flow plans to evaluate its platform for additional neuropsychiatric indications, including traumatic brain injury, addiction, and sleep disorders, potentially expanding the therapeutic applications of at-home neuromodulation technology.